

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Itraconazole 10mg/ml oral solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml Itraconazole oral solution contains 10mg itraconazole. Excipients with known effect:

Each ml of Itraconazole oral solution contains

247mg of sorbitol E420,

400 mg hydroxypropyl- β (cyclodextrin),

103.6mg of propylene glycol (E 1520).

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Oral solution.

Itraconazole oral solution is a clear, yellow solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Itraconazole oral solution is indicated:

- For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.
- As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. < 500 cells/microlitre). At present there are insufficient clinical efficacy data in the prevention of aspergillosis.

Itraconazole oral solution is indicated for use in adults.

Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.

4.2 Posology and method of administration

For optimal absorption, Itraconazole oral solution should be taken without food (patients are advised to refrain from eating for at least 1 hour after intake).

A graduated measuring cup is provided to measure out the correct dose.

For the treatment of oral and/or oesophageal candidosis, the liquid should be swished around the oral cavity (approx. 20 seconds) and swallowed. There should be no rinsing after swallowing.

Treatment of oral and/or oesophageal candidosis: 200 mg (20 ml) per day in two intakes, or alternatively in one intake, for 1 week. If there is no response after 1 week, treatment should be continued for another week.

Treatment of fluconazole resistant oral and/or oesophageal candidosis: 100 to 200 mg (10-20 ml) twice daily for 2 weeks. If there is no response after 2 weeks, treatment should be continued for another 2 weeks. The 400mg daily dose should not be used for longer than 14 days if there are no signs of improvement.

Prophylaxis of fungal infections: 5 mg/kg per day administered in two intakes. In clinical trials, prophylaxis treatment was started immediately prior to the cytostatic treatment and generally one week before transplant procedure. Almost all proven deep fungal infections occurred in patients reaching neutrophil counts below 100 cells/ μ l. Treatment was continued until recovery of neutrophils (i.e. > 1000 cells/ μ l).

Pharmacokinetic parameters from clinical studies in neutropenic patients demonstrate considerable intersubject variation. Blood level monitoring should be considered particularly in the presence of gastrointestinal damage, diarrhoea and during prolonged courses of Itraconazole oral solution.

Use in patients with gastro-intestinal motility impairment

When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility, patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.

Use in children

Since clinical data on the use of itraconazole oral solution in paediatric patients is limited, its use in children is not recommended unless the potential benefit outweighs the potential risks. (See section 4.4) Currently available data are described in section 4.4 and 5.2 but no recommendation on a posology can be made.

Prophylaxis of fungal infections: there are no efficacy data available in neutropenic children. Limited safety experience is available with a dose of 5 mg/kg per day administered in two intakes. (See section 4.8)

Use in elderly

Since clinical data on the use of Itraconazole oral solution in elderly patients is limited, it is advised to use Itraconazole oral solution in these patients only if the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy (See section 4.4).

Use in patients with hepatic impairment

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See section 5.2)

Use in patients with renal impairment

Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.

Method of administration

Precautions to be taken before handling or administering the medicinal product

For instructions on handling of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Itraconazole oral solution is contraindicated in patients with a known hypersensitivity to itraconazole or to any of the excipients listed in section 6.1.

Itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections (see section 4.4 Special warnings and precautions for use).

Itraconazole oral solution should not be used during pregnancy for non-life-threatening indications (see section 4.6).

Co-administration of a number of CYP3A4 substrates is contraindicated with Itraconazole Oral Solution (see sections 4.4 and 4.5). These include:

Analgesics Anaesthetics				
--------------------------------	--	--	--	--

Ergot alkaloids (e.g. dihydroergotamine, ergometrine, ergotamine, methylergometrine)				
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use				
Isavuconazole				
Anthelmintics; Antiprotozoals				
Halofantrine				
Antihistamines for Systemic Use				
Astemizole	Mizolastine	Terfenadine		
Antineoplastic Agents				
Irinotecan	Venetoclax (in patients with chronic lymphocytic leukaemia during initiation and dose titration phase of venetoclax)			
Antithrombotic Agents				
Dabigatran	Ticagrelor			
Antivirals for Systemic Use				
Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)				
Cardiovascular System(Agents Acting on the Renin-Angiotensin System; Antihypertensives; BetaBlockingAgents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)				
Aliskiren	Eplerenone	Quinidine		
Bepridil	Finerenone	Ranolazine		
Disopyramide	Ivabradine	Sildenafil (pulmonary hypertension)		
Dofetilide	Lercanidipine			
Dronedarone	Nisoldipine			
Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders				
Cisapride	Domperidone	Naloxegol		
Immuno suppressants				
Voclosporin				
Lipid Modifying Agents				
Lovastatin	Lomitapide			Simvastatin
Psychoanaleptics; Psycholeptics(e.g.,antipsychotics ,anxiolytics, andhypnotics)				
Lurasidone	Pimozide	Sertindole		
Midazolam (oral)	Quetiapine	Triazolam		
Urologicals				
Avanafil	Darifenacin	Solifenacin (in patients with severe renal impairment or moderate to severe hepatic impairment)		
Dapoxetine	Fesoterodine	Vardenafil (in		

	(in patients with moderate or severe renal or hepatic impairment).	patients older than 75 years).		
Miscellaneous Drugs and Other Substances				
Colchicine (in patients with renal or hepatic impairment)	Eliglustat (in patients that are CYP2D6 poor metabolisers (PM), CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) that are taking a strong or moderate CYP2D6 inhibitor).			

4.4 Special warnings and precautions for use

Use in patients with gastro-intestinal motility impairment

When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility, patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.

Cross-hypersensitivity

There is no information regarding cross hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used in prescribing Itraconazole Oral Solution to patients with hypersensitivity to other azoles.

Cardiac effects

In a healthy volunteer study with Itraconazole IV, a transient asymptomatic decrease of the left ventricular ejection fraction was observed.

Itraconazole has been shown to have a negative inotropic effect and has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of itraconazole.

Itraconazole oral solution should not be used in patients with congestive heart failure or with a history of congestive heart failure unless the benefit clearly outweighs the risk. This individual benefit/risk assessment should take into consideration factors such as the severity of the indication, the dose and duration of the treatment, and individual risk factors for congestive heart failure. Such patients should be informed of the signs and symptoms of congestive heart failure, should be treated with caution, and should be monitored for signs and symptoms of congestive heart failure during treatment; if such signs or symptoms do occur during treatment, Itraconazole oral solution should be discontinued.

Caution should be exercised when co-administering itraconazole and calcium channel blockers (see section 4.5).

Hepatic effects

Very rare cases of serious hepatotoxicity, including some cases of fatal acute liver failure, have occurred with the use of Itraconazole. Some of these cases involved patients with no pre-existing liver disease. Some of these cases have been observed within the first month of treatment, including some within the first week. Liver function monitoring should be considered in patients receiving itraconazole treatment. Patients should be instructed to promptly report to their physician signs and

symptoms suggestive of hepatitis such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine. In these patients treatment should be stopped immediately and liver function testing should be conducted. Most cases of serious hepatotoxicity involved patients who had pre-existing liver disease, were treated for systemic indications, had significant other medical conditions and/or were taking other hepatotoxic drugs.

Paediatric population

Clinical data on the use of Itraconazole oral solution in paediatric patients is limited. The use of Itraconazole oral solution in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks.

Use in elderly

Since clinical data on the use of Itraconazole oral solution in elderly patients is limited, it is advised to use Itraconazole oral solution in these patients only if the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see section 4.4).

Hepatic impairment

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when the drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4.

In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with Itraconazole is strongly discouraged unless there is a serious or life threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications (see section 5.2).

Renal impairment

Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.

Prophylaxis in neutropenic patients

In clinical trials diarrhoea was the most frequent adverse event. This disturbance of the gastrointestinal tract may result in impaired absorption and may alter the microbiological flora potentially favouring fungal colonisation. Consideration should be given to discontinuing Itraconazole oral solution in these circumstances.

Treatment of severely neutropenic patients

Itraconazole oral solution as treatment for oral and/or esophageal candidosis was not investigated in severely neutropenic patients. Due to the pharmacokinetic properties (See 5.2), Itraconazole oral solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidosis.

Hearing Loss

Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see sections 4.3 and 4.5). The hearing loss usually resolves when treatment is stopped, but can persist in some patients.

Cystic fibrosis

In cystic fibrosis patients, variability in plasma levels of itraconazole leading to subtherapeutic concentrations has been observed. The risk for subtherapeutic concentrations may be higher in < 16 year olds. If a patient does not respond to Itraconazole oral solution, consideration should be given to switching to alternative therapy.

Neuropathy

If neuropathy occurs that may be attributable to Itraconazole oral solution, the treatment should be discontinued.

Cross-resistance

In systemic candidosis, if fluconazole-resistant strains of *Candida* species are suspected, it cannot be assumed that these are sensitive to itraconazole, hence their sensitivity should be tested before the start of itraconazole therapy

Interaction potential

Co-administration of specific drugs with itraconazole may result in changes in efficacy or safety of itraconazole and/or the co-administered drug. For example, the use of itraconazole with CYP3A4 inducing agents may lead to sub-therapeutic plasma concentrations of itraconazole and thus treatment failure. In addition, the use of itraconazole with some substrates of CYP3A4 can lead to increases in plasma concentrations of these drugs and to serious and/or potentially life threatening adverse events, such as QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. The prescriber should refer to the co-administered medicinal product information for further information regarding serious or life threatening adverse events that could occur in cases of increased plasma concentrations for that medication. For recommendations concerning the co-administration of medicinal products which are contraindicated, not recommended or recommended for use with caution in combination with itraconazole please refer to sections 4.3 and 4.5.

Interchangeability

It is not recommended that Itraconazole Capsules and Itraconazole Oral Solution be used interchangeably. This is because drug exposure is greater with the Oral Solution than with the Capsules when the same dose of drug is given.

Excipients of Itraconazole Oral Solution

Sorbitol
Itraconazole Oral solution contains 9880 mg sorbitol in each 40ml dose which is equivalent to 247 mg/ml. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be considered. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.

Cyclodextrins

Itraconazole Oral solution contains 16 000 mg cyclodextrin(s) in each 40 mL dose which is equivalent to 400 mg/mL. Cyclodextrins may cause digestive problems such as diarrhoea. There is insufficient information on the effects of cyclodextrin in children <2 years old. Therefore, a case by case judgement should be made regarding the risk/benefit for the patient with Itraconazole Oral solution (see section 4.2).

Propylene Glycol

Itraconazole Oral solution contains 4144mg propylene glycol per 40 ml solution (maximum single dose) which is equivalent to 103.6 mg/ml. and must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (see section 4.3). Itraconazole Oral solution must not be used during lactation (see section 4.6).

Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce adverse effects in children less than 5 years old. Monitoring is required in patients with hepatic or renal impairment because adverse events attributed to propylene glycol have been reported, such as renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.

Sodium

Itraconazole Oral solution contains less than 1mmol sodium (23mg) per ml, that is to say essentially "sodium free".

4.5 Interaction with other medicinal products and other forms of interaction

Itraconazole is mainly metabolized through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole.

Itraconazole is a strong CYP3A4 inhibitor and a P-glycoprotein inhibitor and Breast Cancer Resistance Protein (BCRP) inhibitor. Itraconazole may modify the pharmacokinetics of other substances that share this metabolic or these protein transporter pathways.

Examples of drugs that may impact on the plasma concentration of itraconazole are presented by drug class in Table 1 below. Examples of drugs that may have their plasma concentrations impacted by itraconazole are presented in Table 2 below.

Due to the number of interactions, the potential changes in safety or efficacy of the interacting drugs are not included.

The list of examples of interacting drugs in the tables below is not comprehensive and therefore the product information of each drug that is co-administered with itraconazole should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.

The interactions described in these tables are categorized as contraindicated, not recommended or to be used with caution with itraconazole taking into account the extent of the concentration increase and the safety profile of the interacting drug (see also sections 4.3 and 4.4 for further information). The interaction potential of the listed drugs was evaluated based on human pharmacokinetic studies with itraconazole, and/or human pharmacokinetic studies with other strong CYP3A4 inhibitors (e.g., ketoconazole) and/or in vitro data:

- 'Contraindicated': Under no circumstances is the drug to be co-administered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.
- 'Not recommended': It is recommended that the use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If co-administration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured.
- 'Use with caution': Careful monitoring is recommended when the drug is co-administered with itraconazole. Upon co-administration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured.

The interactions listed in these tables have been characterised in studies that were performed with recommended doses of itraconazole. However, the extent of interaction may be dependent on the dose of itraconazole administered. A stronger interaction may occur at a higher dose or with a shorter dosing interval. Extrapolation of the findings with other dosing scenarios or different drugs should be done with caution.

Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. In patients with hepatic cirrhosis or in subjects receiving CYP3A4 inhibitors, the decline in plasma concentrations may be even more gradual. This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole. (see section 5.2)

Table 1: Examples of drugs that may impact the plasma concentrations of itraconazole, presented by drug class:

Medicinal products Per Orale [PO] Single Dose unless otherwise stated) within class	Expected/Potential effect on itraconazole levels (↑=increase; ↔=nochange; ↓=decrease)	Clinical comment (see above for additional info and also sections 4.3 and 4.4)
Anti-bacterials for Systemic Use; Anti-mycobacterials		
Isoniazid	Although not studied directly, isoniazid is likely to decrease the concentrations of itraconazole.	Not recommended
Rifampicin PO 600 mg OD	Itraconazole AUC ↓	Not recommended
Rifabutin PO 300 mg OD	Itraconazole C _{max} ↓ 71%, AUC ↓ 74%	Not recommended
Ciprofloxacin PO 500 mg BID	Itraconazole C _{max} ↑ 53%, AUC ↑ 82%	Use with caution

Erythromycin 1 g	Itraconazole Cmax ↑ 44%, AUC ↑ 36%	Use with caution
Clarithromycin PO 500 mg BID	Itraconazole Cmax ↑ 90%, AUC ↑ 92%	Use with caution
Antiepileptics		
Carbamazepine, Phenobarbital	Although not studied directly, these drugs are likely to decrease concentrations of itraconazole.	Not recommended
Phenytoin PO 300 mg OD	Itraconazole Cmax ↓ 83%, AUC ↓ 93% Hydroxyitraconazole Cmax ↓ 84%, AUC ↓ 95%	Not recommended
Antineoplastics Agents		
Idelalisib	Although not studied directly, idelalisib is likely to increase the concentrations of itraconazole.	Use with caution
Antivirals for Systemic Use		
Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)	Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.	Contraindicated
Efavirenz 600 mg	Itraconazole Cmax ↓ 37%, AUC ↓ 39%; Hydroxyitraconazole Cmax ↓ 35%, AUC ↓ 37%	Not recommended
Nevirapine PO 200 mg OD	Itraconazole Cmax ↓ 38%, AUC ↓ 62%	Not recommended
Cobicistat, Darunavir (boosted), Elvitegravir (ritonavir-boosted), Fosamprenavir (ritonavir-boosted), Ritonavir, Saquinavir (ritonavir-boosted)	Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.	Use with caution
Indinavir PO 800 mg TID	Itraconazole concentration ↑	Use with caution
Calcium Channel Blockers		
Diltiazem	Although not studied directly, diltiazem is likely to increase the concentration of itraconazole.	Use with caution
Drugs for Acid Related Disorders		
Antacids (aluminium, calcium, magnesium, or sodium bicarbonate), H ₂ -receptor antagonists (e.g., cimetidine, ranitidine), Proton pump inhibitors (e.g., lansoprazole, omeprazole, rabeprazole)	Itraconazole Cmax ↓, AUC ↓	Use with caution
Respiratory System :Other Respiratory System Products		
Lumacaftor/Ivacaftor PO 200/250 mg BID	Itraconazole concentration ↓	Not recommended
Miscellaneous		
St. John's Wort (<i>Hypericum perforatum</i>)	Although not studied directly, St. John's Wort is likely to decrease the concentration of itraconazole.	Not recommended

Table 2: Examples of drugs that may have their plasma concentrations impacted by itraconazole, presented by drug class

Medicinal products (PO SingleDose unless otherwise stated) within class	Expected/Potential effect on drug levels (↑ = increase; ↔ = no change; ↓ = decrease)	Clinical comment (see above for additional info and also sections 4.3 and 4.4)
Analgesics; Anaesthetics		
Ergot alkaloids (eg, dihydroergotamine, ergometrine, ergotamine, methylethergometrine)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated

Eletriptan, Fentanyl	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Alfentanil, Buprenorphine (IV and sublingual), Cannabinoids, Methadone, Sufentanil	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Oxycodone PO 10 mg,	Oxycodone PO: Cmax ↑ 45%, AUC ↑ 2.4- fold	Use with caution
Oxycodone IV 0.1 mg/kg	Oxycodone IV: AUC ↑ 51%	Use with caution
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use		
Isavuconazole	Although not studied directly, itraconazole is likely to increase the concentrations of isavuconazole.	Contraindicated
Bedaquiline	Although not studied directly, itraconazole is likely to increase the concentrations of bedaquiline.	Not recommended
Rifabutin PO 300 mg OD	Rifabutin concentration ↑ (extent unknown)	Not recommended
Clarithromycin PO 500 mg BID	Clarithromycin concentration ↑	Use with caution
Delamanid	Although not studied directly, itraconazole is likely to increase the concentrations of delamanid.	Use with caution
Antiepileptics		
Carbamazepine	Although not studied directly, itraconazole is likely to increase the concentrations of carbamazepine.	Not recommended
Anti-inflammatory and Antirheumatic Products		
Meloxicam 15 mg	Meloxicam Cmax ↓ 64%, AUC ↓ 37%	Use with caution
Anthelmintics; Antiprotozoals		
Halofantrine	Although not studied directly, itraconazole is likely to increase the concentrations of halofantrine.	Contraindicated

Artemether-lumefantrine, Praziquantel	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Quinine 300 mg	Quinine C _{max} ↔, AUC ↑ 96%	Use with caution
Antihistamines for Systemic Use		
Astemizole, Mizolastine, Terfenadine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Ebastine 20 mg	Ebastine C _{max} ↑ 2.5-fold, AUC ↑ 6.2-fold Carebastine C _{max} ↔, AUC ↑ 3.1-fold	Not recommended
Bilastine, Rupatadine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Antineoplastic Agents		
Irinotecan	Although not studied directly, itraconazole is likely to increase the concentrations of irinotecan and its active metabolite.	Contraindicated
Venetoclax	Although not studied directly, itraconazole is likely to increase the concentrations of venetoclax.	Contraindicated in patients with chronic lymphocytic leukaemia during initiation and dose titration phase of venetoclax. Otherwise, not recommended unless the benefits outweigh the risks. Refer to the venetoclax prescribing information.
Axitinib, Bosutinib, Cabazitaxel, Cabozantinib, Ceritinib, Crizotinib, Dabrafenib, Dasatinib, Docetaxel, Everolimus, Ibrutinib, Lapatinib, Nilotinib, Pazopanib, Regorafenib, Sunitinib, Temsirolimus, Trabectedin, Trastuzumab emtansine, Vinca alkaloids (eg, vinflunine, vinorelbine)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs except for cabazitaxel and	Not recommended

	regorafenib. No statistically significant change in cabazitaxel exposure, but a high variability in the results was observed. Regorafenib AUC is expected to decrease (by estimation of active moiety)	
Cobimetinib 10 mg	Cobimetinib Cmax ↑ 3.2-fold, AUC ↑ 6.7-fold	Not recommended
Entrectinib	Entrectinib Cmax ↑ 73%, AUC ↑ 6.0-fold	Not recommended
Olaparib 100 mg	Olaparib Cmax ↑ 40%, AUC ↑ 2.7-fold	Not recommended
Talazoparib	Talazoparib Cmax ↑ 40%, AUC ↑ 56%	Not recommended
Alitretinoin (oral), Bortezomib, Brentuximab vedotin, Erlotinib, Idelalisib, Imatinib, Nintedanib, Panobinostat, Ponatinib, Ruxolitinib, Sonidegib, Tretinoin (oral)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs	Use with caution
Busulfan 1 mg/kg Q6h	Busulfan Cmax ↑, AUC ↑	Use with caution
Gefitinib 250 mg	Gefitinib 250 mg Cmax ↑, AUC ↑ 78%	Use with caution
Pemigatinib	Pemigatinib Cmax ↑ 17%, AUC ↑ 91%	Use with caution
AntithromboticAgents		
Dabigatran, Ticagrelor	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Apixaban, Edoxaban, Rivaroxaban, Vorapaxar	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Cilostazol, Coumarins (e.g., warfarin)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs	Use with caution
AntiviralsforSystemicUse		
Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)	Itraconazole may increase paritaprevir	Contraindicated

	concentrations.	
Elbasvir/Grazoprevir, Tenofovir alafenamide fumarate (TAF), Tenofovir disoproxil fumarate (TDF)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Cobicistat, Elvitegravir (ritonavir- boosted), Glecaprevir/Pibrentasvir, Maraviroc, Ritonavir, Saquinavir	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Indinavir PO 800 mg TID	Indinavir C _{max} ↔, AUC ↑	Use with caution
Cardiovascular System(Agents Acting on the Renin-Angiotensin System;Anti hypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)		
Bepidil, Disopyramide, Dofetilide, Dronedarone, Eplerenone, Finerenone, Ivabradine, Lercanidipine, Nisoldipine, Ranolazine, Sildenafil (pulmonary hypertension)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Aliskiren 150 mg	Aliskiren C _{max} ↑ 5.8-fold, AUC ↑ 6.5-fold	Contraindicated
Quinidine 100 mg	Quinidine C _{max} ↑ 59%, AUC ↑ 2.4-fold	Contraindicated
Felodipine 5 mg	Felodipine C _{max} ↑ 7.8-fold, AUC ↑ 6.3-fold	Not recommended
Riociguat, Tadalafil (pulmonary hypertension)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Bosentan, Diltiazem, Guanfacine, Other Dihydropyridines (e.g., amlodipine, isradipine, nifedipine, nimodipine), Verapamil	Although not studied directly, itraconazole is likely to increase the concentrations of bosentan.	Use with caution
Digoxin 0.5 mg	Digoxin C _{max} ↑ 34%, AUC ↑ 68%	Use with caution
Nadolol 30 mg	Nadolol C _{max} ↑ 4.7-fold, AUC ↑ 2.2-fold	Use with caution
Corticosteroids for Systemic Use;Drugs for Obstructive Airway Diseases		
Ciclesonide, Salmeterol	Although not studied directly, itraconazole is likely to increase the concentrations of salmeterol and the active metabolite of	Not recommended

	ciclesonide.	
Budesonide INH 1 mg SD	Budesonide INH Cmax ↑ 65%, AUC ↑ 4.2- fold; Budesonide (other formulations) concentration ↑	Use with caution
Dexamethasone IV 5 mg Dexamethasone PO 4.5 mg	Dexamethasone IV: Cmax ↔, AUC ↑ 3.3- fold Dexamethasone PO: Cmax ↑ 69%, AUC ↑ 3.7-fold	Use with caution
Fluticasone INH 1 mg BID	Fluticasone INH concentration ↑	Use with caution
Methylprednisolone 16 mg	Methylprednisolone PO Cmax ↑ 92%, AUC ↑ 3.9-fold Methylprednisolone IV AUC ↑ 2.6-fold	Use with caution
Fluticasone nasal	Although not studied directly, itraconazole is likely to increase the concentrations of nasally-administered fluticasone.	Use with caution
Drugs Used in Diabetes		
Repaglinide 0.25 mg	Repaglinide Cmax ↑ 47%, AUC ↑ 41%	Use with caution
Saxagliptin	Although not studied directly, itraconazole is likely to increase the concentrations of saxagliptin.	Use with caution
Gastrointestinal Drugs,including Antidiarrheals,Intestinal Anti-inflammatory/Anti-infectiveA gents;Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders		
Cisapride, Naloxegol	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Domperidone 20 mg	Domperidone Cmax ↑ 2.7-fold, AUC ↑ 3.2- fold	Contraindicated
Aprepitant, Loperamide, Netupitant	Although not studied directly, itraconazole is likely to increase the concentrations of aprepitant.	Use with caution
Immuno suppressants		
Voclosporin	Although not studied directly, itraconazole is likely	Contraindicated

	to increase the concentrations of voclosporin.	
Sirolimus (rapamycin)	Although not studied directly, itraconazole is likely to increase the concentrations of sirolimus.	Not recommended
Cyclosporine, Tacrolimus	Although not studied directly, itraconazole is likely to increase the concentrations of cyclosporine.	Use with caution
Tacrolimus IV 0.03 mg/kg OD	Tacrolimus IV concentration ↑	Use with caution
Lipid Modifying Agents		
Lomitapide	Although not studied directly, itraconazole is likely to increase the concentrations of lomitapide.	Contraindicated
Lovastatin 40 mg,	Lovastatin C _{max} ↑ 14.5->20-fold, AUC ↑ >14.8 - >20-fold Lovastatin acid C _{max} ↑ 11.5-13-fold, AUC ↑ 15.4-20-fold	Contraindicated
Simvastatin 40 mg	Simvastatin acid C _{max} ↑ 17-fold, AUC ↑ 19-fold	Contraindicated
Atorvastatin	Atorvastatin acid: C _{max} ↔ to 12.5-fold, AUC ↑ 40% to 3-fold	Not recommended
Psychoanaleptics; Psycholeptics(e.g.,antipsychotics, anxiolytics, and hypnotics)		
Lurasidone, Pimozide, Quetiapine, Sertindole	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Midazolam (oral) 7.5 mg	Midazolam (oral) C _{max} ↑ 2.5 to 3.4-fold, AUC ↑ 6.6 to 10.8-fold	Contraindicated
Triazolam 0.25 mg	Triazolam C _{max} ↑, AUC ↑	Contraindicated
Alprazolam 0.8 mg	Alprazolam C _{max} ↔, AUC ↑ 2.8-fold	Use with caution
Aripiprazole 3 mg	Aripiprazole C _{max} ↑ 19%, AUC ↑ 48%	Use with caution
Brotizolam 0.5 mg	Brotizolam C _{max} ↔, AUC ↑ 2.6-fold	Use with caution
Buspirone 10 mg	Buspirone C _{max} ↑ 13.4-fold, AUC ↑ 19.2- fold	Use with caution

Midazolam (iv) 7.5 mg	Midazolam (iv) 7.5 mg: concentration ↑; Although not studied directly, itraconazole is likely to increase the concentrations of midazolam following oromucosal administration.	Use with caution
Risperidone 2-8 mg/day	Risperidone and active metabolite concentration ↑	Use with caution
Zopiclone 7.5 mg	Zopiclone C _{max} ↑ 30%, AUC ↑ 70%	Use with caution
Cariprazine, Galantamine, Haloperidol, Reboxetine, Venlafaxine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Respiratory System : Other Respiratory System Products		
Lumacaftor/Ivacaftor PO 200/250 mg BID	Ivacaftor C _{max} ↑ 3.6-fold, AUC ↑ 4.3-fold Lumacaftor C _{max} ↔, AUC ↔	Not recommended
Ivacaftor	Although not studied directly, itraconazole is likely to increase the concentrations of ivacaftor.	Use with caution
Sex Hormones and Modulators of the Genital System; Other Gynaecologicals		
Cabergoline, Dienogest, Ulipristal	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Urologicals		
Avanafil, Dapoxetine, Darifenacin	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Fesoterodine	Although not studied directly, itraconazole is likely to increase the concentrations of the active metabolites, 5-hydroxymethyl tolterodine.	Moderate or severe renal or hepatic impairment: Contraindicated Mild renal or hepatic impairment: Concomitant use should be avoided

		Normal renal or hepatic function: Use with caution with a maximum fesoterodine dose of 4 mg.
Solifenacin	Although not studied directly, itraconazole is likely to increase the concentrations of solifenacin.	Severe renal impairment: Contraindicated Moderate or severe hepatic impairment: Contraindicated Use with caution in all other patients with a maximum solifenacin dose of 5 mg.
Vardenafil	Although not studied directly, itraconazole is likely to increase the concentrations of vardenafil.	Contraindicated in patients older than 75 years; otherwise not recommended.
Alfuzosin, Silodosin, Tadalafil (erectile dysfunction and benign prostatic hyperplasia), Tamsulosin, Tolterodine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Dutasteride, Imidafenacin, Sildenafil (erectile dysfunction)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Oxybutynin 5 mg	Oxybutynin C _{max} ↑ 2-fold, AUC ↑ 2-fold N-desethyloxybutynin C _{max} ↔, AUC ↔ Following transdermal administration: Although not studied directly, itraconazole is likely to increase the concentrations of oxybutynin following transdermal administration.	Use with caution
Miscellaneous Drugs and Other Substances		
Colchicine	Although not studied directly, itraconazole is likely to increase the concentrations of	Contraindicated in patients with renal or hepatic impairment. Not recommended in

	colchicine	other patients.
Eliglustat	Although not directly studied, itraconazole is expected to increase the concentrations of eliglustat.	Contraindicated in CYP2D6 poor metabolisers (PM). Contraindicated in CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor. Use with caution in CYP2D6 IMs and EMs. In CYP2D6 EMs with mild hepatic impairment, an eliglustat dose of 84 mg/day should be considered.
Cinacalcet	Although not studied directly, itraconazole is likely to increase the concentrations of cinacalcet.	Use with caution

4.6 Fertility, pregnancy and lactation

Pregnancy:

Itraconazole oral solution must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (see section 4.3).

In animal studies itraconazole has shown reproduction toxicity (see section 5.3).

Epidemiological data on exposure to Itraconazole during the first trimester of pregnancy – mostly in patients receiving short-term treatment for vulvovaginal candidosis – did not show an increased risk for malformations as compared to control subjects not exposed to any known teratogens. Itraconazole has been shown to cross the placenta in a rat model.

Women of child-bearing potential:

Women of childbearing potential taking Itraconazole oral solution should use contraceptive precautions. Effective contraception should be continued until the next menstrual period following the end of Itraconazole therapy.

Breast Feeding:

A very small amount of itraconazole is excreted in human milk. Itraconazole Oral Solution must not be used during lactation.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

When driving vehicles and operating machinery the possibility of adverse reactions such as dizziness, visual disturbances and hearing loss (see Section 4.8 Undesirable effects), which may occur in some instances, must be taken into account.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse drug reactions (ADRs) with Itraconazole Oral Solution treatment identified from clinical trials and/or from spontaneous reporting were dizziness, headache, dysgeusia, dyspnoea, cough, abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, rash, and pyrexia. The most serious ADRs were serious allergic reactions, cardiac failure/congestive heart failure/pulmonary oedema, pancreatitis, serious hepatotoxicity (including some cases of fatal acute liver failure), and serious skin reactions. Refer to subsection Tabulated list of adverse reactions for the frequencies and for other observed ADRs. Refer to section 4.4 (Special warnings and precautions for use) for additional information on other serious effects.

Tabulated list of adverse reactions

The ADRs in the table below were derived from double-blind and open-label clinical trials with Itraconazole involving 889 patients for the treatment of oropharyngeal and oesophageal candidiasis, and from spontaneous reporting.

The table below presents adverse drug reactions by System Organ Class. Within each System Organ Class, the ADRs are presented by incidence, using the following convention:

Very common ($\geq 1/10$); Common ($\geq 1/100$ to $< 1/10$); Uncommon ($\geq 1/1,000$ to $< 1/100$); Rare ($\geq 1/10,000$ to $< 1/1,000$); Very rare ($< 1/10,000$), Not known (cannot be estimated from the available data).

Adverse Drug Reactions	
Blood and lymphatic system disorders	
<i>Uncommon</i>	Leukopenia, Thrombocytopenia
Immune system disorders	
<i>Uncommon</i>	Hypersensitivity*
<i>Not Known</i>	Serum Sickness, Angioneurotic Oedema, Anaphylactic Reaction, Anaphylactoid Reaction,
Metabolism and nutrition disorders	
<i>Uncommon</i>	Hypokalaemia
<i>Not Known</i>	Hypertriglyceridemia
Nervous system disorders	
<i>Common</i>	Headache, Dizziness, Dysgeusia
<i>Uncommon</i>	Peripheral Neuropathy*, Paraesthesia, Hypoaesthesia
Eye disorders	
<i>Uncommon</i>	Visual Disturbances, including Vision Blurred and Diplopia
Ear and labyrinth disorder	
<i>Uncommon</i>	Tinnitus
<i>Not Known</i>	Transient or permanent hearing loss*
Cardiac disorders	
<i>Uncommon</i>	Cardiac failure
<i>Not Known</i>	Congestive Heart Failure*
Respiratory, thoracic and mediastinal disorders	
<i>Common</i>	Dyspnoea, cough
Gastrointestinal disorders	
<i>Common</i>	Abdominal Pain, Vomiting, Nausea, Diarrhoea, Dyspepsia
<i>Uncommon</i>	Constipation
<i>Not Known</i>	Pancreatitis
Hepato-biliary disorders	
<i>Uncommon</i>	Hepatic failure*, Hyperbilirubinaemia

Not Known	Serious Hepatotoxicity* including some cases of fatal Acute hepatic failure*
Skin and subcutaneous tissue disorders	
Common	Rash
Uncommon	Urticaria, Pruritus
Not Known	Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity
Musculoskeletal and connective tissue disorders	
Uncommon	Myalgia, arthralgia
Reproductive system and breast disorders	
Uncommon	Menstrual disorders,
General disorders and administration site conditions	
Common	Pyrexia
Uncommon	Oedema
Investigations	
Not Known	Blood creatine phosphokinase increased

* see section 4.4.

Description of selected adverse events

The following is a list of additional ADRs associated with itraconazole that have been reported in clinical trials of Itraconazole Capsules and Itraconazole IV, excluding the ADR term "Injection site inflammation", which is specific to the injection route of administration.

Infections and infestations: Sinusitis, Upper respiratory tract infection, Rhinitis

Blood and lymphatic system disorders: Granulocytopenia

Immune system disorders: Anaphylactoid reaction

Metabolism and nutrition disorders: Hyperglycaemia, Hyperkalaemia, Hypomagnesaemia

Psychiatric disorders: Confusional state

Nervous system disorders: Somnolence, Tremor

Cardiac disorders: Left ventricular failure, Tachycardia

Vascular disorders: Hypertension, Hypotension

Respiratory, thoracic and mediastinal disorders: Pulmonary oedema, Dysphonia

Gastrointestinal disorders: Gastrointestinal disorder, Flatulence

Hepatobiliary disorders: Hepatitis, Jaundice, Hepatic function abnormal

Skin and subcutaneous tissue disorders: Rash erythematous, Hyperhidrosis

Renal and urinary disorders: Renal impairment, Pollakiuria, Urinary incontinence

Reproductive system and breast disorders: Erectile dysfunction

General disorders and administration site conditions: Generalised oedema, Face oedema, Chest pain, Pain, Fatigue, Chills

Investigations: Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Blood lactate dehydrogenase increased, Blood urea increased, Gamma-glutamyltransferase increased, Hepatic enzyme increased, Urine analysis abnormal

Paediatric Population

The safety of Itraconazole oral solution was evaluated in 250 paediatric patients aged 6 months to 14 years who participated in five open-label clinical trials. These patients received at least one dose of itraconazole for prophylaxis of fungal infections or for treatment of oral thrush or systemic fungal infections and provided safety data.

Based on pooled safety data from these clinical trials, the very common reported ADRs in paediatric patients were Vomiting (36.0%), Pyrexia (30.8%), Diarrhoea (28.4%), Mucosal inflammation (23.2%), Rash (22.8%), Abdominal pain (17.2%), Nausea (15.6%), Hypertension (14.0%), and Cough (11.2%). The nature of ADRs in paediatric patients is similar to that observed in adult subjects, but the incidence is higher in the paediatric patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the following:

IE: HPRA Pharmacovigilance, Website: www.hpra.ie.

4.9 Overdose

Symptoms:

In general, adverse events reported with overdose have been consistent with adverse drug reactions already listed in this SmPC for itraconazole (see section 4.8).

Treatment:

In the event of an overdose, supportive measures should be employed. Itraconazole cannot be removed by haemodialysis. No specific antidote is available.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antimycotic for systemic use, triazole derivative.

ATC code: J02A C02

Mechanism of action

Itraconazole inhibits fungal 14 α -demethylase, resulting in a depletion of ergosterol and disruption of membrane synthesis by fungi.

PK/PD relationship

The PK/PD relationship for itraconazole, and for triazoles in general, is poorly understood and is complicated by limited understanding of antifungal pharmacokinetics.

Mechanism(s) of resistance

Resistance of fungi to azoles appears to develop slowly and is often the result of several genetic mutations. Mechanisms that have been described are

- Over-expression of *ERG11*, the gene that encodes 14-alpha-demethylase (the target enzyme)
- Point mutations in *ERG11* that lead to decreased affinity of 14-alpha-demethylase for itraconazole
- Drug-transporter over-expression resulting in increased efflux of itraconazole from fungal cells (i.e., removal of itraconazole from its target)
- Cross-resistance. Cross-resistance amongst members of the azole class of drugs has been observed within *Candida* species though resistance to one member of the class does not necessarily confer resistance to other azoles.

Breakpoints

Breakpoints for itraconazole have been established in the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for antifungal agents, version 10.0, valid from 2020-02-04.

Candida and Aspergillus species	Minimal Inhibitory Concentration (MIC) breakpoint (mg/L)	
	≤ S (Susceptible)	> R (Resistant)
<i>Candida albicans</i>	0.06	0.06
<i>Candida dubliniensis</i>	0.06	0.06
<i>Candida parapsilosis</i>	0.125	0.125
<i>Candida tropicalis</i>	0.125	0.125
<i>Aspergillus flavus</i> ^{1,2}	1	1

<i>Aspergillus fumigatus</i> ^{1,2}	1	1
<i>Aspergillus nidulans</i> ^{1,2}	1	1
<i>Aspergillus terreus</i> ^{1,2}	1	1

There is currently insufficient evidence to set clinical breakpoints for *Candida glabrata*³, *C. krusei*³, *C. guilliermondii*³, *Cryptococcus neoformans*, and Non-species related breakpoints for *Candida*.

There is currently insufficient evidence to set clinical breakpoints for *Aspergillus niger*^{4,5} and Non-species related breakpoints for *Aspergillus* spp.⁵.

¹ Monitoring of azole trough concentrations in patients treated for fungal infection is recommended.

²Area of technical uncertainty (ATU) is 2. Report as R with the following comment: "In some clinical situations (non-invasive infections forms) itraconazole can be used provided sufficient exposure is ensured".

³ The epidemiological cut-off values (ECOFFs) for these species are in general higher than for *C. albicans*.

⁴ The epidemiological cut-off values (ECOFFs) for these species are in general one two-fold dilution higher than for *A. fumigatus*.

⁵ The MIC values for isolates of *A. niger* and *A. versicolor* are in general higher than those for *A. fumigatus*. Whether this translates into a poorer clinical response is unknown.

Interpretive breakpoints for itraconazole have not been established for *Candida* species and filamentous fungi, using Clinical and Laboratory Standards Institute (CLSI) methods, M60 Performance Standards for Antifungal Susceptibility Testing of Yeasts. 2nd edition, 2020.

The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

The *in vitro* susceptibility of fungi to itraconazole depends on the inoculum size, incubation temperature, growth phase of the fungi, and the culture medium used. For these reasons, the minimum inhibitory concentration of itraconazole may vary widely. Susceptibility in the table below is based on MIC₉₀ < 1 mg itraconazole/L. There is no correlation between *in vitro* susceptibility and clinical efficacy.

Commonly susceptible species
<i>Aspergillus</i> spp. ²
<i>Blastomyces dermatitidis</i> ¹
<i>Candida albicans</i>
<i>Candida parapsilosis</i>
<i>Cladosporium</i> spp.
<i>Coccidioides immitis</i> ¹
<i>Cryptococcus neoformans</i>
<i>Epidermophyton floccosum</i>
<i>Fonsecaea</i> spp. ¹
<i>Geotrichum</i> spp.
<i>Histoplasma</i> spp.
<i>Malassezia</i> (formerly <i>Pityrosporum</i>) spp.
<i>Microsporium</i> spp.
<i>Paracoccidioides brasiliensis</i> ¹
<i>Penicillium marneffeii</i> ¹
<i>Pseudallescheria boydii</i>
<i>Sporothrix schenckii</i>
<i>Trichophyton</i> spp.
<i>Trichosporon</i> spp.
Species for which acquired resistance may be a problem
<i>Candida glabrata</i> ³
<i>Candida krusei</i>
<i>Candida tropicalis</i> ³

Inherently resistant organisms

Absidia spp.

Fusarium spp.

Mucor spp.

Rhizomucor spp.

Rhizopus spp.

Scedosporium proliferans

Scopulariopsis spp.

1 These organisms may be encountered in patients who have returned from travel outside Europe.

2 Itraconazole-resistant strains of *Aspergillus fumigatus* have been reported.

3 Natural intermediate susceptibility.

Paediatric Population

The tolerability and safety of itraconazole oral solution was studied in the prophylaxis of fungal infections in 103 neutropenic paediatric patients aged 0 to 14 years (median 5 years) in an open-label uncontrolled phase III clinical study. Most patients (78%) were undergoing allogeneic bone marrow transplantation for haematological malignancies. All patients received 5 mg/kg/day of itraconazole oral solution as a single or divided dose. Due to the design of the study, no formal conclusion with regard to efficacy could be derived. The most common adverse events considered definitely or possibly related to itraconazole were vomiting, abnormal liver function, and abdominal pain.

5.2 Pharmacokinetic propertiesItraconazole*General pharmacokinetic characteristics*

Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing. Steady-state concentrations are generally reached within about 15 days, with C_{max} and AUC values 4 to 7-fold higher than those seen after a single dose. Steady-state C_{max} values of about 2 microgram/ml are reached after oral administration of 200 mg once daily. The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. Itraconazole mean total plasma clearance following intravenous administration is 278 ml/min. Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.

Absorption

Itraconazole is rapidly absorbed after administration of the oral solution. Peak plasma concentrations of the unchanged drug are reached within 2.5 hours following an oral dose under fasting conditions. The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30% when the oral solution is taken in fasting conditions. Itraconazole exposure is greater with the oral solution than with the capsule formulation when the same dose of drug is given. (See section 4.4).

Distribution

Most of the itraconazole in plasma is bound to protein (99.8%) with albumin being the main binding component (99.6% for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (> 700 L), suggesting its extensive distribution into tissues: Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma, but efficacy has been demonstrated against infections present in the cerebrospinal fluid.

Metabolism

Itraconazole is extensively metabolised by the liver into a large number of metabolites. The main metabolite is hydroxy-itraconazole, which has *in vitro* antifungal activity comparable to itraconazole. Trough plasma concentrations of the hydroxy-itraconazole are about twice those of itraconazole.

As shown in *in vitro* studies, CYP 3A4 is the major enzyme that is involved in the metabolism of itraconazole.

Elimination

Itraconazole is excreted mainly as inactive metabolites to about 35% in urine and to about 54% with faeces within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabeled dose, faecal excretion of unchanged drug ranges from 3% to 18% of the dose.

As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period.

Special Populations

Hepatic Impairment:

Itraconazole is predominantly metabolised in the liver. A pharmacokinetic study using a single 100 mg dose of itraconazole (one 100 mg capsule) was conducted in 6 healthy and 12 cirrhotic subjects. A statistically significant reduction in average C_{max} (47%) and a two fold increase in the elimination half-life (37 ± 17 versus 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole (see sections 4.2 and 4.4).

Renal Impairment:

Limited data are available on the use of oral itraconazole in patients with renal impairment.

A pharmacokinetic study using a single 200-mg dose of itraconazole (four 50-mg capsules) was conducted in three groups of patients with renal impairment (uremia: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13 ml/min. $\times 1.73 m^2$, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (T_{max} , C_{max} , and AUC_{0-8h}). Plasma concentration-versus-time profiles showed wide intersubject variation in all three groups.

After a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as CrCl 50-79 ml/min), moderate (defined in this study as CrCl 20-49 ml/min), and severe renal impairment (defined in this study as CrCl <20 ml/min) were similar to that in healthy subjects (range of means 42-49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function.

Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the half-life or clearance of itraconazole or hydroxy-itraconazole (see sections 4.2 and 4.4).

Paediatric Population:

Two pharmacokinetic studies have been conducted in neutropenic children aged 6 months to 14 years in which itraconazole oral solution was administered 5 mg/kg once or twice daily. The exposure to itraconazole was somewhat higher in older children (6 to 14 years) compared to younger children. In all children, effective plasma concentrations of itraconazole were reached within 3 to 5 days after initiation of treatment and maintained throughout treatment.

Hydroxypropyl- β -Cyclodextrin

The oral bioavailability of hydroxypropyl- β -cyclodextrin given as a solubilizer of itraconazole in oral solution is on average lower than 0.5% and is similar to that of hydroxypropyl- β -cyclodextrin alone. This low oral bioavailability of hydroxypropyl- β -cyclodextrin is not modified by the presence of food and is similar after single and repeated administrations.

5.3 Preclinical safety data

Itraconazole

Itraconazole is not a primary carcinogen in rats up to 13 mg/kg/day (males) and 52 mg/kg/day (females), or in mice up to 80 mg/kg/day (1-fold of MRHD based on mg/m²/day).

Nonclinical data on itraconazole revealed no indications for gene toxicity, primary carcinogenicity or impairment of fertility. At high doses, of 40 and 80 mg/kg/day in rats (1- and 2-fold of MRHD based on mg/m²/day), effects were observed in the adrenal cortex, liver and the mononuclear phagocyte system but appear to have a low relevance for the proposed clinical use. A global lower bone mineral density was observed in juvenile dogs after chronic itraconazole administration, (no toxicity was

observed up to 20 mg/kg/day (2-fold of MRHD based on mg/m²/day), and in rats, a decreased bone plate activity, thinning of the zona compacta of the large bones, and an increased bone fragility was observed.

Hydroxypropyl-β-cyclodextrin

Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction and development. In a rat carcinogenicity study, hydroxypropyl-β-cyclodextrin produced adenocarcinomas in the large intestine (at the 5 000 mg/kg/day dose (3-fold of MRHD of 16 g based on mg/m²/day)) and exocrine pancreatic adenocarcinomas (at all dose levels tested 500, 2 000 and 5 000 mg/kg/day (0.3-, 1.2- and 3-fold of MRHD of 16 g based on mg/m²/day, respectively)). These findings were not observed in a similar mouse carcinogenicity study. The clinical relevance of the large intestine adenocarcinomas is low and the mechanism of exocrine pancreatic adenocarcinomas induction not considered relevant to humans.

Reproductive toxicology

Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats from 40 mg/kg/day (1-fold of MRHD based on mg/m²/day) and mice from 80 mg/kg/day (1-fold of MRHD based on mg/m²/day). In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and macroglossia. No teratogenic effects were found in rabbits up to 80 mg/kg/day dose (4-fold of MRHD based on mg/m²/day).

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Hydroxypropyl-β-cyclodextrin

Sorbitol 70% (E420)

Propylene glycol

Cherry flavour

Caramel (contains propylene glycol) Sodium

saccharin dihydrate

Hydrochloric acid and sodium hydroxide (for pH adjustment)

Purified water.

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

18 months as packaged for sale.

1 month after first opening the container.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Type III 150 ml amber glass bottle, with child resistant polyethylene screw cap and LDPE internal coating, in a cardboard carton.

A graduated measuring cup is provided. Graduation is from 2.5 - 30ml, initially in 2.5ml and then 5ml intervals.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Athlone Pharmaceuticals Limited

03 January 2025

CRN00FTKF

Page 24 of 25

Connaught House
1 Burlington Road
Dublin 4
D04 C5Y6
Ireland

8 MARKETING AUTHORISATION NUMBER

PA1418/004/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 10th May 2013

Date of last renewal: 5th February 2018

10 DATE OF REVISION OF THE TEXT

December 2024